Latest trends in United States - What people search

cole caufield victor hedman austin slater las vegas aces carmelo anthony tyran stokes cruz azul - necaxa utah royals fc vs seattle reign fc 90 day fiance strait of hormuz oil shock

revolution medicines is searched in United States

Revolution Medicines prices $2B in concurrent stock, notes offerings - MSN

Revolution Medicines prices $2B in concurrent stock, notes offerings

MSN

📢 Published on 📅 April 26, 2026 🕒 22:04

AbbVie denies it’s in talks to buy Revolution Medicines. Both stocks are falling. - MSN

AbbVie denies it’s in talks to buy Revolution Medicines. Both stocks are falling.

MSN

📢 Published on 📅 April 26, 2026 🕒 11:32

Revolution Medicines shares slide after Merck reportedly walks away from takeover talks - MSN

Revolution Medicines shares slide after Merck reportedly walks away from takeover talks

MSN

📢 Published on 📅 April 26, 2026 🕒 09:14

RVMD stock rallies 41% on positive phase III pancreatic cancer data - MSN

RVMD stock rallies 41% on positive phase III pancreatic cancer data

MSN

📢 Published on 📅 April 26, 2026 🕒 05:42

Revolution Medicines Adds RM-055 And First Line Data To RAS Story - simplywall.st

Revolution Medicines Adds RM-055 And First Line Data To RAS Story

simplywall.st

📢 Published on 📅 April 25, 2026 🕒 21:17

Nicholas Hornstein: Anticipating Resistance and Revolution Medicines' Proactive Strategy for RAS Therapy - Oncodaily

Nicholas Hornstein: Anticipating Resistance and Revolution Medicines' Proactive Strategy for RAS Therapy

Oncodaily

📢 Published on 📅 April 25, 2026 🕒 16:42

Ben Sasse was given a few months to live. He credits "providence, prayer and a miracle drug" for giving him more time. - CBS News

Ben Sasse was given a few months to live. He credits "providence, prayer and a miracle drug" for giving him more time.

CBS News

📢 Published on 📅 April 24, 2026 🕒 22:02

Merck in talks to buy Revolution Medicines for around $30 billion - MSN

Merck in talks to buy Revolution Medicines for around $30 billion

MSN

📢 Published on 📅 April 24, 2026 🕒 08:32

The 'unprecedented' cancer test results that sent Revolution Medicines flying - MSN

The 'unprecedented' cancer test results that sent Revolution Medicines flying

MSN

📢 Published on 📅 April 24, 2026 🕒 03:52

Why these treatments for one of the deadliest cancers are stirring such hope - The Washington Post

Why these treatments for one of the deadliest cancers are stirring such hope

The Washington Post

📢 Published on 📅 April 23, 2026 🕒 22:20

M&T Bank Corp Acquires New Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat

M&T Bank Corp Acquires New Holdings in Revolution Medicines, Inc. $RVMD

MarketBeat

📢 Published on 📅 April 23, 2026 🕒 10:18

At AACR, talk of Chinese biotech, oncology’s comms issue, and more - statnews.com

At AACR, talk of Chinese biotech, oncology’s comms issue, and more

statnews.com

📢 Published on 📅 April 22, 2026 🕒 18:42

Revolution Medicines slips as investors digest recent $2.2B financing and spending outlook - Quiver Quantitative

Revolution Medicines slips as investors digest recent $2.2B financing and spending outlook

Quiver Quantitative

📢 Published on 📅 April 22, 2026 🕒 17:36

HC Wainwright Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD) - MarketBeat

HC Wainwright Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)

MarketBeat

📢 Published on 📅 April 22, 2026 🕒 12:27

Revolution Medicines ASCO Data Readouts Sharpen RAS Oncology Investment Story - simplywall.st

Revolution Medicines ASCO Data Readouts Sharpen RAS Oncology Investment Story

simplywall.st

📢 Published on 📅 April 22, 2026 🕒 08:15

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Rating of "Buy" from Brokerages

MarketBeat

📢 Published on 📅 April 22, 2026 🕒 06:12

Revolution Medicines unveils new RAS cancer inhibitor class By Investing.com - Investing.com South Africa

Revolution Medicines unveils new RAS cancer inhibitor class By Investing.com

Investing.com South Africa

📢 Published on 📅 April 22, 2026 🕒 02:50

Revolution Medicines presents pancreatic cancer trial data at AACR By Investing.com - Investing.com South Africa

Revolution Medicines presents pancreatic cancer trial data at AACR By Investing.com

Investing.com South Africa

📢 Published on 📅 April 22, 2026 🕒 02:37

RVMD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

RVMD Financials: Income Statement, Balance Sheet & Cash Flow

Stock Titan

📢 Published on 📅 April 22, 2026 🕒 01:48

Revolution Medicines unveils new RAS cancer inhibitor class By Investing.com - Investing.com Australia

Revolution Medicines unveils new RAS cancer inhibitor class By Investing.com

Investing.com Australia

📢 Published on 📅 April 22, 2026 🕒 01:14

From Revolution Medicines, more strong data on KRAS drug and a glimpse of a 'novel class' beyond it - statnews.com

From Revolution Medicines, more strong data on KRAS drug and a glimpse of a 'novel class' beyond it

statnews.com

📢 Published on 📅 April 21, 2026 🕒 23:05

Revolution Medicines presents pancreatic cancer trial data at AACR By Investing.com - Investing.com India

Revolution Medicines presents pancreatic cancer trial data at AACR By Investing.com

Investing.com India

📢 Published on 📅 April 21, 2026 🕒 22:56

Revolution Medicines presents pancreatic cancer trial data at AACR By Investing.com - Investing.com Canada

Revolution Medicines presents pancreatic cancer trial data at AACR By Investing.com

Investing.com Canada

📢 Published on 📅 April 21, 2026 🕒 22:35

At AACR, more strong results for Revolution Medicine's KRAS drug, plus assurance from NCI's director - statnews.com

At AACR, more strong results for Revolution Medicine's KRAS drug, plus assurance from NCI's director

statnews.com

📢 Published on 📅 April 21, 2026 🕒 22:24

Revolution Medicines, Inc. Bonds — Corporate Bond Rates - TradingView

Revolution Medicines, Inc. Bonds — Corporate Bond Rates

TradingView

📢 Published on 📅 April 21, 2026 🕒 22:18

Revolution Medicines unveils new RAS cancer inhibitor class - Investing.com

Revolution Medicines unveils new RAS cancer inhibitor class

Investing.com

📢 Published on 📅 April 21, 2026 🕒 21:57

AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises - Fierce Biotech

AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises

Fierce Biotech

📢 Published on 📅 April 21, 2026 🕒 21:35

Pancreatic cancer drug posts 58% response with chemo in early trial - Stock Titan

Pancreatic cancer drug posts 58% response with chemo in early trial

Stock Titan

📢 Published on 📅 April 21, 2026 🕒 21:35

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting - Yahoo Finance

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

Yahoo Finance

📢 Published on 📅 April 21, 2026 🕒 21:30

Revolution Medicines to present phase 3 pancreatic cancer data at ASCO - Investing.com

Revolution Medicines to present phase 3 pancreatic cancer data at ASCO

Investing.com

📢 Published on 📅 April 21, 2026 🕒 18:53

Is this pancreatic cancer's 'Herceptin moment'? Revolution Medicines' breakthrough offers hope - Endpoints News

Is this pancreatic cancer's 'Herceptin moment'? Revolution Medicines' breakthrough offers hope

Endpoints News

📢 Published on 📅 April 21, 2026 🕒 15:38

Revolution Medicines to present phase 3 pancreatic cancer data at ASCO - Investing.com UK

Revolution Medicines to present phase 3 pancreatic cancer data at ASCO

Investing.com UK

📢 Published on 📅 April 21, 2026 🕒 15:30

Pancreatic cancer drug survival data gets ASCO plenary slot - Stock Titan

Pancreatic cancer drug survival data gets ASCO plenary slot

Stock Titan

📢 Published on 📅 April 21, 2026 🕒 15:23

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting - Yahoo Finance

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

Yahoo Finance

📢 Published on 📅 April 21, 2026 🕒 15:23

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting - ChartMill

ChartMill

📢 Published on 📅 April 21, 2026 🕒 15:23

Mass General Brigham Inc Takes Position in Revolution Medicines, Inc. $RVMD - MarketBeat

Mass General Brigham Inc Takes Position in Revolution Medicines, Inc. $RVMD

MarketBeat

📢 Published on 📅 April 21, 2026 🕒 10:53

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting - Sahm

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

Sahm

📢 Published on 📅 April 21, 2026 🕒 07:00

AACR 2026 – Revolution’s second project impresses again | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

AACR 2026 – Revolution’s second project impresses again | ApexOnco - Clinical Trials news and analysis

Oncology Pipeline

📢 Published on 📅 April 20, 2026 🕒 11:22

Revolution Medicines (RVMD) Jumps 54% on Stellar Drug Trial Results - Yahoo Finance

Revolution Medicines (RVMD) Jumps 54% on Stellar Drug Trial Results

Yahoo Finance

📢 Published on 📅 April 20, 2026 🕒 01:03

AACR 2026: More strong data for Revolution Medicines’ KRAS drug - statnews.com

AACR 2026: More strong data for Revolution Medicines’ KRAS drug

statnews.com

📢 Published on 📅 April 19, 2026 🕒 21:50

Revolution Medicines reports phase 1 data for lung cancer drug - Investing.com

Revolution Medicines reports phase 1 data for lung cancer drug

Investing.com

📢 Published on 📅 April 19, 2026 🕒 18:32

Revolution Medicines Updates Phase 1 Clinical Data for Zoldonrasib in KRAS G12D Non-Small Cell Lung Cancer at AACR 2026 - Quiver Quantitative

Revolution Medicines Updates Phase 1 Clinical Data for Zoldonrasib in KRAS G12D Non-Small Cell Lung Cancer at AACR 2026

Quiver Quantitative

📢 Published on 📅 April 19, 2026 🕒 18:10

Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting - GlobeNewswire

Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting

GlobeNewswire

📢 Published on 📅 April 19, 2026 🕒 18:00

Experimental lung cancer pill posts 52% response in treated patients - Stock Titan

Experimental lung cancer pill posts 52% response in treated patients

Stock Titan

📢 Published on 📅 April 19, 2026 🕒 18:00

Revolution Medicines (RVMD) Valuation After Strong Phase 3 RASolute 302 Pancreatic Cancer Results - simplywall.st

Revolution Medicines (RVMD) Valuation After Strong Phase 3 RASolute 302 Pancreatic Cancer Results

simplywall.st

📢 Published on 📅 April 19, 2026 🕒 17:41

Revolution Medicines (RVMD) Valuation After Strong Phase 3 RASolute 302 Pancreatic Cancer Results - Sahm

Revolution Medicines (RVMD) Valuation After Strong Phase 3 RASolute 302 Pancreatic Cancer Results

Sahm

📢 Published on 📅 April 19, 2026 🕒 07:00

Revolution Medicines’ Daraxonrasib Nearly Doubles Survival in KRAS-Mutant Pancreatic Cancer - Oncodaily

Revolution Medicines’ Daraxonrasib Nearly Doubles Survival in KRAS-Mutant Pancreatic Cancer

Oncodaily

📢 Published on 📅 April 18, 2026 🕒 15:59

Revolution Medicines (RVMD) Is Up 54.1% After Positive Daraxonrasib Phase 3 Data And $2B Fundraise - simplywall.st

Revolution Medicines (RVMD) Is Up 54.1% After Positive Daraxonrasib Phase 3 Data And $2B Fundraise

simplywall.st

📢 Published on 📅 April 18, 2026 🕒 08:20

Jim Cramer Shares Why Revolution Medicines (RVMD) is Extraordinary - Yahoo Finance

Jim Cramer Shares Why Revolution Medicines (RVMD) is Extraordinary

Yahoo Finance

📢 Published on 📅 April 18, 2026 🕒 07:00

Revolution Medicines (RVMD) director exercises 120K options, sells 120K shares under 10b5-1 plan - Stock Titan

Revolution Medicines (RVMD) director exercises 120K options, sells 120K shares under 10b5-1 plan

Stock Titan

📢 Published on 📅 April 17, 2026 🕒 23:26

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - GlobeNewswire

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

📢 Published on 📅 April 17, 2026 🕒 20:02

Pancreatic cancer data, the RAS bonanza and China ADC standouts are ready for AACR - Endpoints News

Pancreatic cancer data, the RAS bonanza and China ADC standouts are ready for AACR

Endpoints News

📢 Published on 📅 April 17, 2026 🕒 15:38

A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment - statnews.com

A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment

statnews.com

📢 Published on 📅 April 17, 2026 🕒 07:00

Revolution Medicines (NASDAQ: RVMD) issues $500M 0.50% convertible notes due 2033 - Stock Titan

Revolution Medicines (NASDAQ: RVMD) issues $500M 0.50% convertible notes due 2033

Stock Titan

📢 Published on 📅 April 17, 2026 🕒 07:00

Revolution Medicines raises $2.1B in stock and debt offerings - Investing.com

Revolution Medicines raises $2.1B in stock and debt offerings

Investing.com

📢 Published on 📅 April 17, 2026 🕒 07:00

Cancer drug developer pulls in $2.2B from stock and note sales - Stock Titan

Cancer drug developer pulls in $2.2B from stock and note sales

Stock Titan

📢 Published on 📅 April 17, 2026 🕒 07:00

Is It Too Late To Consider Revolution Medicines (RVMD) After A 321.4% One Year Surge? - simplywall.st

Is It Too Late To Consider Revolution Medicines (RVMD) After A 321.4% One Year Surge?

simplywall.st

📢 Published on 📅 April 16, 2026 🕒 13:42

Why Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib Data - Yahoo Finance

Why Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib Data

Yahoo Finance

📢 Published on 📅 April 16, 2026 🕒 07:00

Revolution Medicines (RVMD) adds $1.65B equity plus $500M in 0.50% convertible notes - Stock Titan

Revolution Medicines (RVMD) adds $1.65B equity plus $500M in 0.50% convertible notes

Stock Titan

📢 Published on 📅 April 16, 2026 🕒 07:00

Revolution Medicines announces mega-bucks proposed share offerings - The Pharma Letter

Revolution Medicines announces mega-bucks proposed share offerings

The Pharma Letter

📢 Published on 📅 April 16, 2026 🕒 07:00

Latham Advises Revolution Medicines on Concurrent Upsized Offerings of Common Stock - Latham & Watkins LLP

Latham Advises Revolution Medicines on Concurrent Upsized Offerings of Common Stock

Latham & Watkins LLP

📢 Published on 📅 April 15, 2026 🕒 18:23

Revolution Medicines’ $1.5B follow-on highest to date - BioWorld News

Revolution Medicines’ $1.5B follow-on highest to date

BioWorld News

📢 Published on 📅 April 15, 2026 🕒 07:00

Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo - Sahm

Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo

Sahm

📢 Published on 📅 April 14, 2026 🕒 12:54

Revolution Medicines (RVMD) Is Up 42.9% After Phase 3 Daraxonrasib Survival Data And $750M Equity Raise – Has The Bull Case Changed? - Yahoo Finance

Revolution Medicines (RVMD) Is Up 42.9% After Phase 3 Daraxonrasib Survival Data And $750M Equity Raise – Has The Bull Case Changed?

Yahoo Finance

📢 Published on 📅 April 14, 2026 🕒 07:00

For Ben Sasse, Revolution Medicines’ pancreatic cancer trial felt like his best, only option - statnews.com

For Ben Sasse, Revolution Medicines’ pancreatic cancer trial felt like his best, only option

statnews.com

📢 Published on 📅 April 14, 2026 🕒 07:00

Revolution Medicines' experimental cancer pill boosts survival in late-stage study - Reuters

Revolution Medicines' experimental cancer pill boosts survival in late-stage study

Reuters

📢 Published on 📅 April 14, 2026 🕒 07:00

PanCAN Statement on Positive Overall Survival Results from Revolution Medicines Phase III Trial - Pancreatic Cancer Action Network

PanCAN Statement on Positive Overall Survival Results from Revolution Medicines Phase III Trial

Pancreatic Cancer Action Network

📢 Published on 📅 April 14, 2026 🕒 07:00

Revolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions Underway (RVMD) - Seeking Alpha

Revolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions Underway (RVMD)

Seeking Alpha

📢 Published on 📅 April 14, 2026 🕒 07:00

Cancer drug developer Revolution Medicines locks in $2B financing - Stock Titan

Cancer drug developer Revolution Medicines locks in $2B financing

Stock Titan

📢 Published on 📅 April 14, 2026 🕒 07:00

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes - Yahoo Finance

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

Yahoo Finance

📢 Published on 📅 April 14, 2026 🕒 07:00

Revolution Medicines plans $1B combined equity and convertible note offerings - MSN

Revolution Medicines plans $1B combined equity and convertible note offerings

MSN

📢 Published on 📅 April 13, 2026 🕒 21:05

Revolution Medicines Reports ‘Unprecedented’ Survival in Pivotal Pancreatic Cancer Trial - MedCity News

Revolution Medicines Reports ‘Unprecedented’ Survival in Pivotal Pancreatic Cancer Trial

MedCity News

📢 Published on 📅 April 13, 2026 🕒 19:55

Revolution Medicines jumps 35% as investors focus on near-term clinical catalysts for daraxonrasib - Quiver Quantitative

Revolution Medicines jumps 35% as investors focus on near-term clinical catalysts for daraxonrasib

Quiver Quantitative

📢 Published on 📅 April 13, 2026 🕒 14:49

Revolution rises 40% as pancreatic cancer drug doubles survival - BioSpace

Revolution rises 40% as pancreatic cancer drug doubles survival

BioSpace

📢 Published on 📅 April 13, 2026 🕒 14:15